Michael Gold to Antineoplastic Agents
This is a "connection" page, showing publications Michael Gold has written about Antineoplastic Agents.
Connection Strength
0.421
-
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.
Score: 0.166
-
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003 Aug; 90(2):325-30.
Score: 0.143
-
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004 Feb; 103(2):317-26.
Score: 0.037
-
Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25.
Score: 0.030
-
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
Score: 0.028
-
A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013 May; 208(5):410.e1-6.
Score: 0.017